206 related articles for article (PubMed ID: 31771696)
1. IOX-101 Reverses Drug Resistance Through Suppression of Akt/mTOR/NF-κB Signaling in Cancer Stem Cell-Like, Sphere-Forming NSCLC Cell.
Fayi MA; Alamri A; Rajagopalan P
Oncol Res; 2020 Mar; 28(2):177-189. PubMed ID: 31771696
[TBL] [Abstract][Full Text] [Related]
2. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
Shi H; Pu J; Zhou XL; Ning YY; Bai C
Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
[TBL] [Abstract][Full Text] [Related]
3. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
4. Glutathione Peroxidase 1 Promotes NSCLC Resistance to Cisplatin via ROS-Induced Activation of PI3K/AKT Pathway.
Chen B; Shen Z; Wu D; Xie X; Xu X; Lv L; Dai H; Chen J; Gan X
Biomed Res Int; 2019; 2019():7640547. PubMed ID: 31032363
[TBL] [Abstract][Full Text] [Related]
5. Targeting CD133 reverses drug-resistance via the AKT/NF-κB/MDR1 pathway in colorectal cancer.
Yuan Z; Liang X; Zhan Y; Wang Z; Xu J; Qiu Y; Wang J; Cao Y; Le VM; Ly HT; Xu J; Li W; Yin P; Xu K
Br J Cancer; 2020 Apr; 122(9):1342-1353. PubMed ID: 32203206
[TBL] [Abstract][Full Text] [Related]
6. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
7. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells.
Lu R; Zhao G; Yang Y; Jiang Z; Cai J; Hu H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819864311. PubMed ID: 31405336
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of AKT/NF‑κB signaling by eurycomalactone decreases human NSCLC cell viability and improves the chemosensitivity to cisplatin.
Dukaew N; Chairatvit K; Pitchakarn P; Imsumran A; Karinchai J; Tuntiwechapikul W; Wongnoppavich A
Oncol Rep; 2020 Oct; 44(4):1441-1454. PubMed ID: 32945500
[TBL] [Abstract][Full Text] [Related]
10. [The reversing and molecular mechanisms of miR-503 on the drug-resistance to cisplatin in A549/DDP cells].
Wu Y; Guo L; Liu J; Liu R; Liu M; Chen J
Zhongguo Fei Ai Za Zhi; 2014 Jan; 17(1):1-7. PubMed ID: 24398307
[TBL] [Abstract][Full Text] [Related]
11. miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway.
Liu J; Xing Y; Rong L
Oncol Rep; 2018 Apr; 39(4):1631-1639. PubMed ID: 29484437
[TBL] [Abstract][Full Text] [Related]
12. The role of emodin on cisplatin resistance reversal of lung adenocarcinoma A549/DDP cell.
Teng X; Wang SY; Shi YQ; Fan XF; Liu S; Xing Y; Guo YY; Dong M
Anticancer Drugs; 2021 Oct; 32(9):939-949. PubMed ID: 34001704
[TBL] [Abstract][Full Text] [Related]
13. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
Zhou W; Wang J; Man WY; Zhang QW; Xu WG
Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
Feng FF; Cheng P; Sun C; Wang H; Wang W
Chin J Nat Med; 2019 Oct; 17(10):768-777. PubMed ID: 31703757
[TBL] [Abstract][Full Text] [Related]
15. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
[TBL] [Abstract][Full Text] [Related]
16. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
[TBL] [Abstract][Full Text] [Related]
17. Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
Hu Y; Zang J; Cao H; Wu Y; Yan D; Qin X; Zhou L; Fan F; Ni J; Xu X; Sha H; Liu S; Yu S; Wang Z; Ma R; Wu J; Feng J
Oncotarget; 2017 Feb; 8(9):15802-15814. PubMed ID: 28178657
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
19. BRM270 inhibits cancer stem cell maintenance via microRNA regulation in chemoresistant A549 lung adenocarcinoma cells.
Kwon T; Chandimali N; Huynh DL; Zhang JJ; Kim N; Bak Y; Yoon DY; Yu DY; Lee JC; Gera M; Ghosh M; Park YH; Jeong DK
Cell Death Dis; 2018 Feb; 9(2):244. PubMed ID: 29445170
[TBL] [Abstract][Full Text] [Related]
20. [The effect and mechanism of vinorelbine on cisplatin resistance of human lung cancer cell line A549/DDP].
Qi C; Gao S; Li H; Gao W
Zhongguo Fei Ai Za Zhi; 2014 Feb; 17(2):148-54. PubMed ID: 24581167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
